NewsBenzingaOS Therapies Says FDA's Shelving Of Commissioner's National Priority Voucher Has No Impact On Its Rare Pediatric Disease PRV Prospects OS Therapies Says FDA's Shelving Of Commissioner's National Priority Voucher Has No Impact On Its Rare Pediatric Disease PRV Prospects Benzinga 2026.11.13 13:37 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Kodiak AI, Lowers Price Target to $7 Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says